Navigation Links
Reportlinker Adds Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017
Date:5/5/2011

NEW YORK, May 5, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

http://www.reportlinker.com/p0490349/Tumor-Markers---Global-Pipeline-Analysis-Competitive-Landscape-and-Market-Forecasts-to-2017.html

Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

Summary

GlobalData's new report, "Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017" provides key data, information and analysis on the global tumor markers market. The report provides market landscape, competitive landscape and market trends information on the tumor markers market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape and technology offerings.

While tumor markers have been part of the global cancer diagnostics market since the 1960s, their popularity as therapeutic targets has only risen in the last few decades, primarily due to the increasing prevalence and mortality related to cancer. Cancer is currently the second leading cause of death in most developed countries of the world such as the US, the UK and so on, and is one of the most researched disease areas in the pharmaceutical and biotechnology industry. The global tumor markers market was estimated at $1 billion in 2010 and is expected to grow at a CAGR (compound annual growth rate) of over 6% till 2017. The tumor markers market is poised for rapid growth as researchers approach major technological breakthroughs in tumor diagnosis and therapy, the discovery of new specific antigens, and the genetic basis of cancer. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, the early detection of tumors, and monitoring biological responses to cancer therapy.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

- Key geographies covered include the US, Canada, the UK, Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

- Annualized market revenues data from 2003 to 2010, forecast forward for 7 years to 2017. Company shares data for 2010.

- Qualitative analysis of key market trends, market drivers, and restraints by each category within tumor markers market.

- The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.

- Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories, Fujirebio Inc., bioMerieux SA and Beckman Coulter.

Reasons to buy

- Develop business strategies by understanding the trends and developments that are driving the tumor markers market globally.

- Design and develop your product development, marketing and sales strategies.

- Develop market-entry and market expansion strategies.

- Identify key players best positioned to take advantage of the emerging market opportunities.

- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.

- What's the next big thing in the tumor markers market landscape? – Identify, understand and capitalize.

- Make more informed business decisions from the insightful and in-depth analysis of the global tumor markers market and the factors shaping it.

1 Table of contents

1 Table of contents 3

1.1 List of Tables 8

1.2 List of Figures 10

2 Introduction 11

2.1 GlobalData Report Guidance 11

3 Disease Overview: Cancer 12

3.1 Etiology 12

3.2 Types of cancers 12

3.2.1 Classification by Histology 12

3.2.2 Cancer Types by Site 13

3.3 Cancer Signs and Symptoms 14

3.4 Cancer Diagnosis 14

3.5 Epidemiology 15

4 Tumor Markers Overview 18

4.1 Tumor Markers: Technology Overview 18

4.1.1 Introduction 18

4.1.2 Types of Tumor Markers 18

4.1.3 Applications 18

5 Tumor Markers: Global Market Characterization 20

5.1 Tumor Markers Market, Global, Revenue ($m), Historic, 2003 ? 2010 20

5.2 Tumor Markers Market, Global, Revenue ($m), Forecast, 2010 ? 2017 21

5.3 Tumor Markers, Key Market Trends 22

5.3.1 Increasing Investments by Private Equity (PE) /Venture Capital (VC) Firms in Startups is Driving Innovation and Market Growth 22

5.3.2 Novel Tumor Markers Makes Diagnostic Test for Ovarian Cancer More Efficient 22

5.4 Tumor Markers, Market Dynamics 23

5.4.1 Market Drivers 23

5.4.2 Market Restraints 27

5.5 Tumor Markers Market, Opportunities and Unmet Needs 28

5.5.1 Opportunities: Highly Fragmented Market to Provide a Significant Opportunity for Big Tumor Marker Manufacturers 28

5.5.2 Unmet Needs 28

6 Tumor Markers Market, by Country, Revenue ($m), 2003 – 2017 29

6.1 Tumor Markers Market, The US, Revenue ($m), Historic, 2003–2010 29

6.2 Tumor Markers Market, The US, Revenue ($m), Forecast, 2010–2017 30

6.3 Tumor Markers Market, Canada, Revenue ($m), Historic, 2003–2010 31

6.4 Tumor Markers Market, Canada, Revenue ($m), Forecast, 2010–2017 32

6.5 Tumor Markers Market, The UK, Revenue ($m), Historic, 2003-2010 33

6.6 Tumor Markers Market, The UK, Revenue ($m), Forecast, 2010-2017 34

6.7 Tumor Markers Market, Germany, Revenue ($m), Historic, 2003-2010 35

6.8 Tumor Markers Market, Germany, Revenue ($m), Forecast, 2010-2017 36

6.9 Tumor Markers Market, France, Revenue ($m), Historic, 2003- 2010 37

6.10 Tumor Markers Market, France, Revenue ($m), Forecast, 2010-2017 38

6.11 Tumor Markers Market, Italy, Revenue ($m), Historic, 2003-2010 39

6.12 Tumor Markers Market, Italy, Revenue ($m), Forecast, 2010-2017 40

6.13 Tumor Markers Market, Spain, Revenue ($m), Historic, 2003-2010 41

6.14 Tumor Markers Market, Spain, Revenue ($m), Forecast, 2010-2017 42

6.15 Tumor Markers Market, Japan, Revenue ($m), Historic, 2003-2010 43

6.16 Tumor Markers Market, Japan, Revenue ($m), Forecast, 2010-2017 44

6.17 Tumor Markers Market, China, Revenue ($m), Historic, 2003-2010 45

6.18 Tumor Markers Market, China, Revenue ($m), Forecast, 2010-2017 46

6.19 Tumor Markers Market, India, Revenue ($m), Historic, 2003-2010 47

6.20 Tumor Markers Market, India, Revenue ($m), Forecast, 2010-2017 48

6.21 Tumor Markers Market, Australia, Revenue ($m), Historic, 2003-2010 49

6.22 Tumor Markers Market, Australia, Revenue ($m), Forecast, 2010-2017 50

6.23 Tumor Markers Market, Brazil, Revenue ($m), Historic, 2003-2010 51

6.24 Tumor Markers Market, Brazil, Revenue ($m), Forecast, 2010-2017 52

7 Tumor Markers Market: Competitive Landscape 53

7.1 Tumor Markers Market, Key Company Share (%), 2010 53

7.2 Abbott Laboratories (Abbott) 54

7.2.1 Company Overview 54

7.2.2 Marketed Products 54

7.2.3 Pipeline Products 54

7.2.4 SWOT Analysis 55

7.3 F. Hoffman-La Roche 57

7.3.1 Company Overview 57

7.3.2 Marketed Products 57

7.3.3 Pipeline Products 58

7.3.4 SWOT Analysis 58

7.4 Fujirebio Inc. 60

7.4.1 Company Overview 60

7.4.2 Marketed Products 60

7.4.3 SWOT Analysis 61

7.5 bioMerieux S.A. 62

7.5.1 Company Overview 62

7.5.2 Marketed Products 62

7.5.3 Pipeline Products 63

7.5.4 SWOT Analysis 63

7.6 Beckman Coulter 64

7.6.1 Company Overview 64

7.6.2 Marketed Products 64

7.6.3 Pipeline Products 64

7.6.4 SWOT Analysis 65

8 Global Tumor Markers Market: Other Major Companies 67

8.1 Clarient Inc. 67

8.1.1 Company Overview 67

8.1.2 Marketed Products 67

8.1.3 Pipeline Products 67

8.2 Siemens Healthcare 68

8.2.1 Company Overview 68

8.2.2 Marketed Products 68

8.2.3 Pipeline Products 68

8.3 DiaSorin SpA 69

8.3.1 Company Overview 69

8.3.2 Marketed Products 69

8.4 QIAGEN N.V. 70

8.4.1 Company Overview 70

8.4.2 Marketed Products 70

8.4.3 Pipeline Products 70

8.5 Xeptagen SpA 71

8.5.1 Company Overview 71

8.5.2 Marketed Products 71

8.5.3 Pipeline Products 71

9 Global Tumor Markers Market: Strategic Pipeline Assessment 72

9.1 Tumor Markers Market: Pipeline Products summary 72

9.2 Tumor Markers, Pipeline Products by Development Stage, Global, 2010 72

9.3 Tumor Markers Market, Pipeline Products by Therapy Area, Global, 2010 73

10 Tumor Markers- Important Pipeline Products by Company 74

10.1 F.Hoffman La Roche' 74

10.1.1 Integrated Modular Analytics cyfra21-1/NSE Test 74

10.2 bioMerieux S.A. 74

10.2.1 EHT Dx 12 74

10.2.2 EHT Dx 13 74

10.3 Siemens Healthcare 75

10.4 Epigenomics AG 75

10.4.1 Epi proColon-mSEPT9 75

10.4.2 Lung Cancer Screening Test 77

10.5 Xeptagen SpA 78

10.5.1 DCP-IgM Liver cancer Test 78

10.5.2 Multi-Marker biochip 79

10.5.3 SCCA–IgM Pulmonary cancer test 79

10.6 AdnaGen Inc. 79

10.6.1 AdnaTest BreastCancer 79

10.6.2 AdnaTest ColonCancer 83

10.7 QIAGEN N.V. 84

10.7.1 BRaf Test-Colon Cancer 84

10.7.2 EGFR Assay-Lung Cancer 84

10.8 Quanterix corporation 85

10.8.1 AccuPSA Test 85

10.9 Rosetta Genomics 85

10.9.1 miRNA Based Diagnostic Test For Breast Cancer 85

10.10 Oncomethylome Sciences 86

10.10.1 Cervical cancer diagnostic test 86

10.10.2 InformDx - Lung Cancer test 86

10.11 Onconome Inc. 87

10.11.1 ColoMark CCSA-4 Serum Assay 87

10.12 Source MDx 88

10.12.1 Aggressive Cancer Stratification–Prostate Cancer 88

10.12.2 Precision Profile-Prostate Cancer Early Detection 88

10.13 Trovagene, Inc. 89

10.13.1 AML/NPM1-Bone Marrow/Blood 89

10.14 Mitomics Inc. 89

10.14.1 Bladder Cancer-Diagnostic Test 89

10.15 Glycozyme. 89

10.15.1 Breast cancer Biomarker Assay 89

10.16 Neogenix Oncology Corporation 90

10.16.1 Diagnostic Marker-Colorectal Cancer 90

10.17 Exiqon A/S 92

10.17.1 Colon Cancer Recurrence Test 92

10.17.2 miRNA Test-Endometrial Cancer 92

10.18 China Sky One Medical, Inc. 93

10.18.1 Semi-quantitative test for uterine cancer 93

10.18.2 Liver Cancer Diagnostic Kit 93

10.19 Advanced Cell Diagnostics 93

10.19.1 Breast Cancer Test 93

10.20 Zetiq Technologies Ltd 94

10.20.1 CellDetect for Cervical Cancer 94

10.21 Biomoda, Inc. 94

10.21.1 Cypath-bladder cancer diagnostic assay 94

10.22 Predictive Biosciences. Inc. 95

10.22.1 Biomarker mGSTP1-Prostate Cancer 95

10.23 Power3 Medical Products, Inc 95

10.23.1 BC-SeraPro Assay 95

10.24 DiaGenic ASA 96

10.24.1 BCtect 96

10.24.2 Breast Cancer Screening Test 96

10.25 Protagen AG 97

10.25.1 Breast Cancer-Early Diagnosis assay 97

10.26 BioMarCare Technologies Ltd. 97

10.26.1 Breast PARpanel 97

10.27 Akers Biosciences, Inc. 97

10.27.1 Breath PulmoHealth Check 97

10.28 Allegro Diagnostics, Inc. 98

10.28.1 BronchoGen 98

10.29 MabCure, Inc. 99

10.29.1 Diagnostic Test-Breast Carcinoma 99

10.30 Cangen Biotechnologies, Inc. 99

10.30.1 Early Stage Lung Cancer Diagnostic test 99

10.31 Exosome Diagnostics, Inc. 100

10.31.1 EGFR Cancer Gene Mutation test 100

10.32 Exagen Diagnostics, Inc. 101

10.32.1 eXagenBC(ER/PR+) 101

10.33 Martell Biosystems, Inc 101

10.33.1 FACTT-Breast cancer assay 101

10.34 Miraculins Inc. 102

10.34.1 P2V Prostate Cancer Test 102

10.34.2 Gastric Cancer Diagnostic Test 103

10.35 NorDiag ASA 104

10.35.1 Genefec III 104

10.36 A&G Pharmaceutical, Inc. 105

10.36.1 GP88 Blood Diagnostic Test 105

10.37 Expression Pathology Inc. 105

10.37.1 HER2 Assay for Breast Cancer 105

10.38 Milagen, Inc 105

10.38.1 Immunoassay - Colon Cancer 105

10.39 IncellDx, Inc. 106

10.39.1 IncellDx Breast Cancer Test 106

10.40 Gene Express, Inc. 106

10.40.1 Lung Cancer Diagnostic Assay 106

10.41 GenomicTree Inc 106

10.41.1 MDScan Cervical Cancer Screening Test 106

10.42 BIOCRATES Life Sciences AG 107

10.42.1 Metabolomic Biomarker Assay-Cancer 107

10.43 Health Discovery Corporation 107

10.43.1 Molecular diagnostic test-pancreatic cancer 107

10.44 Gene Express, Inc. 107

10.44.1 Molecular Diagnostic Tests for Bladder Cancer 107

10.45 IRIS International, Inc. 110

10.45.1 NADiA ProsVue 110

10.46 Everist Genomics, Inc. 111

10.46.1 OncoDefender-CRC 111

10.47 Orion Genomics LLC 112

10.47.1 Orion Colorectal Cancer Risk Test 112

10.48 Correlogic Systems, Inc. 112

10.48.1 OvaCheck 112

10.49 Arrayit Corporation 112

10.49.1 OvaDx 112

10.50 Protagen AG 113

10.50.1 Ovarian Cancer-Early Diagnosis Assay 113

10.51 HealthLinx Limited 113

10.51.1 OvPlex 2nd Generation 113

10.52 Strategic Diagnostics Inc. 114

10.52.1 Pancreatic Cancer Assay 114

10.53 HistoRx, Inc. 115

10.53.1 PI3K Multimarker Assay 115

10.53.2 PROGENSA PCA3 Assay 115

10.54 Correlogic Systems, Inc. 118

10.54.1 ProstaCheck 118

10.55 AnalizaDx, LLC 118

10.55.1 Prostate Cancer Biomarker Test 118

10.56 Ambrilia Biopharma Inc. 119

10.56.1 PSP94 Immunoassay 119

10.57 BioCurex Inc 119

10.57.1 RECAF Blood Test 119

10.58 Fermiscan Holdings Limited 120

10.58.1 The Fermiscan Test 120

10.59 Nanosphere, Inc. 123

10.59.1 Verisens Ultra-Sensitive PSA Assay 123

11 Global Tumor Markers Market: Deals Landscape 124

11.1 Global Tumor Markers Market: Deals Overview 124

11.2 Global Tumor Markers Market: Key Acquisitions 124

11.2.1 Vivakor Enters Into Memorandum of Understanding to Merge with Resolution Biomedical 124

11.2.2 GE Healthcare Acquires Clarient 124

11.2.3 Danaher to Acquire Beckman Coulter Inc 125

11.2.4 Myriad Genetics to Acquire Novel Technology from Melanoma Diagnostics 125

11.2.5 Fujirebio Acquires Innogenetics from Abbott Laboratories 125

11.3 Global Tumor Markers Market: Partnership Deals 126

11.3.1 UCL Business Enters Into a Licensing Agreement with Becton Dickinson 126

11.3.2 Rosetta Genomics Enters Into an Agreement with Carmel Medical Center 126

11.3.3 Transgene Signs an Agreement with Beckman Coulter Inc 126

11.3.4 Neogenix Oncology Enters an Agreement with IRCCS San Raffaele Pisana 127

11.3.5 Vermillion Enters Into an Agreement with Quest Diagnostics 127

11.3.6 BioMerieux Enters into a Co-Development Agreement with Biocartis 127

11.3.7 Epigenomics Enters Into an Agreement with Pronto Diagnostics 128

11.3.8 Roche Enters into a Licensing agreement with QIAGEN 128

11.3.9 OvaGene Oncology Enters into Licensing Agreement with Bergen Teknologioverforing and Medinnova 128

11.3.10 bioMerieux Signs into a Co-development Agreement with GlaxoSmithKline 129

11.3.11 IDL Biotech Enters into a Licensing Agreement with Radim 129

11.3.12 Sysmex Europe Enters Into an Agreement with Adnagen 129

11.3.13 Immunogenetics Signs an Agreement with Adnagen 130

12 Appendix 131

12.1 Definition 131

12.2 Acronyms 132

12.3 Research Methodology 133

12.4 Secondary Research 133

12.5 Primary Research 133

12.6 Models 134

12.7 Forecasts 134

12.8 Expert Panels 134

12.9 GlobalData Consulting 134

12.10 Contact Us 135

12.11 Disclaimer 135

List of Tables

Table 1: Global Cancer Incidence, Most Common Cancers, by Sex, 2008 16

Table 2: Types of Tumor Markers 18

Table 3: Tumor Markers Market, Global, Revenue ($m), 2003 – 2010 20

Table 4: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017 21

Table 5: Increase in Specificity and Sensitivity, Multi-Marker Tests 23

Table 6: Cancer Incidence, by Geography, (%), 2008 24

Table 7: Tumor Markers Market, The US, Revenue ($m), 2003-2010 29

Table 8: Tumor Markers Market, The US, Revenue ($m), 2010-2017 30

Table 9: Tumor Markers Market, Canada, Revenue ($m), 2003-2010 31

Table 10: Tumor Markers Market, Canada, Revenue ($m), 2010-2017 32

Table 11: Tumor Markers Market, The UK, Revenue ($m), 2003-2010 33

Table 12: Tumor Markers Market, The UK, Revenue ($m), 2010-2017 34

Table 13: Tumor Markers Market, Germany, Revenue ($m), 2003-2010 35

Table 14: Tumor Markers Market, Germany, Revenue ($m), 2010-2017 36

Table 15: Tumor Markers Market, France, Revenue ($m), 2003-2010 37

Table 16: Tumor Markers Market, France, Revenue ($m), 2010-2017 38

Table 17: Tumor Markers Market, Italy, Revenue ($m), 2003-2010 39

Table 18: Tumor Markers Market, Italy, Revenue ($m), 2010-2017 40

Table 19: Tumor Markers Market, Spain, Revenue ($m), 2003-2010 41

Table 20: Tumor Markers Market, Spain, Revenue ($m), 2010-2017 42

Table 21: Tumor Markers Market, Japan, Revenue ($m), 2003-2010 43

Table 22: Tumor Markers Market, Japan, Revenue ($m), 2010-2017 44

Table 23: Tumor Markers Market, China, Revenue ($m), 2003-2010 45

Table 24: Tumor Markers Market, China, Revenue ($m), 2010-2017 46

Table 25: Tumor Markers Market, India, Revenue ($m), 2003-2010 47

Table 26: Tumor Markers Market, India, Revenue ($m), 2010-2017 48

Table 27: Tumor Markers Market, Australia, Revenue ($m), 2003-2010 49

Table 28: Tumor Markers Market, Australia, Revenue ($m), 2010-2017 50

Table 29: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010 51

Table 30: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017 52

Table 31: Tumor Markers Market, Global, Company Revenue ($m), 2010 53

Table 32: Abbott, Tumor Markers, Marketed Products 54

Table 33: Abbott, Tumor Markers, Pipeline Products 54

Table 34: F. Hoffman La Roche, Tumor Markers, Pipeline Products 58

Table 35: Fujirebio, Tumor Markers, Marketed Products 60

Table 36: bioMerieux, Tumor Markers, Marketed Products 62

Table 37: Beckman Coulter, Tumor Markers, Marketed Products 64

Table 38: Clarient, Tumor Markers, Marketed Products 67

Table 39: Siemens Healthcare, Tumor Markers, Marketed Products 68

Table 40: DiaSorin, Tumor Markers, Marketed Products 69

Table 41: QIAGEN, Tumor Markers, Marketed Products 70

Table 42: QIAGEN, Tumor Markers, Pipeline Products 70

Table 43: Xeptagen, Tumor Markers, Marketed Products 71

Table 44: Xeptagen, Tumor Markers, Pipeline Products 71

Table 45: Epi proColon-mSEPT9 - Clinical Trial 75

Table 46: Epi proColon-mSEPT9 - Clinical Trial 76

Table 47: Lung Cancer Screening Test - Clinical Trial 77

Table 48: DCP-IgM Liver Cancer Test - Clinical Trial 78

Table 49: AdnaTest BreastCancer - Clinical Trial 80

Table 50: AdnaTest BreastCancer - Clinical Trial 81

Table 51: AdnaTest BreastCancer - Clinical Trial 82

Table 52: AdnaTest BreastCancer - Clinical Trial 83

Table 53: AdnaTest ColonCancer - Clinical Trial 84

Table 54: ColoMark CCSA-4 Serum Assay - Clinical Trial 87

Table 55: Precision Profile-Prostate Cancer Early Detection Clinical Trial 88

Table 56: Diagnostic Marker-Colorectal Cancer - Clinical Trial 90

Table 57: Diagnostic Marker-Colorectal Cancer - Clinical Trial 91

Table 58: Semi-Quantitative Test for Uterine Cancer - Clinical Trial 93

Table 59: Biomarker mGSTP1-Prostate Cancer - Clinical Trial 95

Table 60: BCtect - Breast Cancer - Clinical Trial 96

Table 61: BronchoGen - Clinical Trial 98

Table 62: Early Stage Lung Cancer Diagnostic test - Clinical Trial 100

Table 63: P2V Prostate Cancer Test - Clinical Trial 102

Table 64: P2V Prostate Cancer Test - Clinical Trial 102

Table 65: Gastric Cancer Diagnostic Test - Clinical Trial 103

Table 66: Genefec III - Clinical Trial 104

Table 67: Genefec III - Clinical Trial 104

Table 68: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial 108

Table 69: Molecular Diagnostic Tests For Bladder Cancer - Clinical Trial 109

Table 70: NADiA ProsVue - Clinical Trial 110

Table 71: OncoDefender-CRC - Clinical Trial 111

Table 72: OvPlex 2nd Generation - Clinical Trial 113

Table 73: OvPlex 2nd Generation - Clinical Trial 114

Table 74: PROGENSA PCA3 Assay - Clinical Trial 115

Table 75: PROGENSA PCA3 Assay - Clinical Trial 116

Table 76: PROGENSA PCA3 Assay - Clinical Trial 116

Table 77: PROGENSA PCA3 Assay - Clinical Trial 117

Table 78: ProstaCheck - Clinical Trial 118

Table 79: PSP94 Immunoassay - Clinical Trial 119

Table 80: The Fermiscan Test - Clinical Trial 120

Table 81: The Fermiscan Test - Clinical Trial 121

Table 82: The Fermiscan Test - Clinical Trial 122

Table 83: Verisens Ultra-Sensitive PSA Assay - Clinical Trial 123

List of Figures

Figure 1: Classification of Cancers, by Tissue of Origin 12

Figure 2: Most Common Types of Cancers, Classification by Primary Site of Origin 13

Figure 3: Cancer Incidence Rate, Global, 2008 15

Figure 4: Cancer Incidence, Global, Most Common Cancers, by Sex, 2008 16

Figure 5: List Of Common Tumor Markers Used for Detection of Multiple Cancers, 2010 19

Figure 6: Tumor Markers Market, Global, Revenue($m), 2003 – 2010 20

Figure 7: Tumor Markers Market, Global, Revenue ($m), 2010 – 2017 21

Figure 8: Tumor Markers, Market Dynamics 23

Figure 9: Cancer Incidence, by Geography, (%), 2008 24

Figure 10: Healthcare Spending Growth Rate (%), Asia-Pacific, 2007-2008 26

Figure 11: Tumor Markers Market, The US, Revenue ($m), 2003-2010 29

Figure 12: Tumor Markers Market, The US, Revenue ($m), 2010-2017 30

Figure 13: Tumor Markers Market, Canada, Revenue ($m), 2003-2010 31

Figure 14: Tumor Markers Market, Canada, Revenue ($m), 2010-2017 32

Figure 15: Tumor Markers Market, The UK, Revenue ($m), 2003-2010 33

Figure 16: Tumor Markers Market, The UK, Revenue ($m), 2010-2017 34

Figure 17: Tumor Markers Market, Germany, Revenue ($m), 2003-2010 35

Figure 18: Tumor Markers Market, Germany, Revenue ($m), 2010-2017 36

Figure 19: Tumor Markers Market, France, Revenue ($m), 2003-2010 37

Figure 20: Tumor Markers Market, France, Revenue ($m), 2010-2017 38

Figure 21: Tumor Markers Market, Italy, Revenue ($m), 2003-2010 39

Figure 22: Tumor Markers Market, Italy, Revenue ($m), 2010-2017 40

Figure 23: Tumor Markers Market, Spain, Revenue ($m), 2003-2010 41

Figure 24: Tumor Markers Market, Spain, Revenue ($m), 2010-2017 42

Figure 25: Tumor Markers Market, Japan, Revenue ($m), 2003-2010 43

Figure 26: Tumor Markers Market, Japan, Revenue ($m), 2010-2017 44

Figure 27: Tumor Markers Market, China, Revenue ($m), 2003-2010 45

Figure 28: Tumor Markers Market, China, Revenue ($m), 2010-2017 46

Figure 29: Tumor Markers Market, India, Revenue ($m), 2003-2010 47

Figure 30: Tumor Markers Market, India, Revenue ($m), 2010-2017 48

Figure 31: Tumor Markers Market, Australia, Revenue ($m), 2003-2010 49

Figure 32: Tumor Markers Market, Australia, Revenue ($m), 2010-2017 50

Figure 33: Tumor Markers Market, Brazil, Revenue ($m), 2003-2010 51

Figure 34: Tumor Markers Market, Brazil, Revenue ($m), 2010-2017 52

Figure 35: Tumor Markers Market, Global, Key Company Share (%), 2010 53

Figure 36: SWOT Analysis, Abbott 55

Figure 37: SWOT Analysis, F. Hoffman La Roche 58

Figure 38: SWOT Analysis, Fujirebio, Inc. 61

Figure 39: SWOT Analysis, bioMerieux SA 63

Figure 40: SWOT Analysis, Beckman Coulter 65

Figure 41: Tumor Markers, Pipeline Products by Development Stage, Global, 2010 72

Figure 42: Tumor Markers, Pipeline Products by Therapy Area, Global, 2010 73

Companies Mentioned

Abbott Laboratories (Abbott)

F. Hoffman-La Roche

Fujirebio Inc.

bioMerieux S.A.

Beckman Coulter

Clarient Inc.

Siemens Healthcare

DiaSorin SpA

QIAGEN N.V.

Xeptagen SpA

To order this report:

: Tumor Markers - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2017

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACT:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related biology technology :

1. Reportlinker Adds Biomarkers: Technologies and Global Markets
2. Reportlinker Adds Medical Enzymes: Technologies and Global Markets
3. Reportlinker Adds Case Study: Personalized Cancer Therapy - The era of biomarker identification and companion diagnostic co-development
4. Reportlinker Adds R&D Trends: Osteoporosis - Strong pipeline bodes well for future treatment
5. Reportlinker Adds Molecular Diagnostics Market: DNA Probes And Biochips
6. Reportlinker Adds Competitor Analysis: Targeted Therapy of Diabetes
7. Reportlinker Adds China Bio-breeding Industry Report, 2010
8. Reportlinker Adds Neurology Devices Market Outlook in China to 2017 - Neurostimulation Devices, Interventional Neurology and Other
9. Reportlinker Adds Biomarker Partnering Terms and Agreements
10. Reportlinker Adds Top & Emerging Bio-Fuel Markets by Technology, Feedstocks, Regulations, Pricing & Commercialization Trends & Forecasts (2011 - 2016)
11. Reportlinker Adds Industrial Biotechnology China News 1103
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Sunnyvale, CA (PRWEB) , ... February 09, 2016 ... ... will present its latest innovations on its free and validated Electronic Data Capture ... Booth #81 the Outsourcing in Clinical Trials West Coast 2016 Conference in San ...
(Date:2/9/2016)... ... 2016 , ... The American Academy of Thermology (AAT) has announced ... AAT Member Certification Qualification Course for Technicians via a two part webinar on July ... a detailed review of hardware, software, and camera setup/operations, aligns with the in-person member ...
(Date:2/9/2016)... , ... February 09, 2016 , ... ... Vice President for Public Policy for the National Organization for Rare Disorders (NORD). ... groups to ensure their voices are heard throughout the drug regulatory review process. ...
(Date:2/9/2016)... , Feb. 9, 2016 This market research ... current and future prospects of the market in terms ... include companies engaged in the manufacture of microbiology culture ... summary with a market snapshot providing the overall information ... this report. This section also provides the overall information ...
Breaking Biology Technology:
(Date:2/2/2016)... Calif. , Feb. 2, 2016  Based ... market, Frost & Sullivan recognizes US-based Intelligent Retinal ... Frost & Sullivan Award for New Product Innovation. ... in North America , is ... the rapidly growing diabetic retinopathy market. The IRIS ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first day ... announced plans to develop a first of its kind ... of IBM Watson. In the first application of ... (NYSE: IBM ), and Welltok will create a ... assessments with cognitive analytics, delivered on Welltok,s health optimization ...
(Date:1/28/2016)... 28, 2016 Synaptics (NASDAQ: SYNA ), a leading ... second quarter ended December 31, 2015. --> ... fiscal 2016 increased 2 percent compared to the comparable quarter last ... fiscal 2016 was $35.0 million, or $0.93 per diluted share. ... for the first quarter of fiscal 2016 grew 9 percent over ...
Breaking Biology News(10 mins):